BioCentury | Jun 23, 2020
Distillery Therapeutics

Repurposing antimalarial drug lumefantrine for glioblastoma

...with other cancer therapies. Novartis AG (NYSE:NVS; SIX:NOVN) markets lumefantrine in combination with artemether as Coartem...
BioCentury | Sep 22, 2017
Clinical News

Novartis starts Phase IIb of KAF156 for malaria

...and Asian trial will enroll about 512 adults, adolescents and children to receive Novartis' Coartem artemether/lumefantrine...
...parasitemia 12, 24 and 48 hours after treatment and pharmacokinetics. KAF156 is an imidazolopiperazine derivative. Coartem...
...24 and 48 hours after treatment and pharmacokinetics Status: Phase IIb started Milestone: NA Elizabeth S. Eaton artemether/lumefantrine Coartem KAF156 Medicines...
BioCentury | Sep 29, 2016
Targets & Mechanisms

Hitting for the cycle

...weeks or months, causing relapses later on. Current therapies, which include Novartis AG 's Coartem artemether/lumefantrine...
BioCentury | Apr 14, 2014
Company News

Novartis, Malaria No More infectious news

...2 million treatments of a pediatric formulation of Novartis' malaria drug Coartem artemether/lumefantrine - called Coartem...
BioCentury | Dec 19, 2013
Targets & Mechanisms

Lipid kinase enters the malaria stage

...only effective against the blood stages of the parasite. Marketed artemisinin derivatives include Novartis' Coartem artemether/lumefantrine...
BioCentury | May 6, 2013
Company News

Novartis, Malaria No More infectious news

...to 3 million courses of a pediatric formulation of malaria drug Coartem artemether/lumefantrine - called Coartem...
BioCentury | Apr 25, 2013
Distillery Techniques

Technology: Chemistry

...artemisinin-based combination therapies to treat malaria infection. Novartis AG markets the artemisinin-based combination therapy Coartem artemether/lumefantrine...
BioCentury | Dec 24, 2012
Clinical News

Kaletra lopinavir/ritonavir: Phase III data

...2 NRTIs had a significant reduction in the incidence of malaria recurrence after treatment with artemether/lumefantrine...
...are both non-nucleoside reverse transcriptase inhibitor (NNRTIs). Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) markets Coartem artemether/lumefantrine...
BioCentury | Sep 13, 2012
Politics & Policy

FDA lowers fee to use Priority Review voucher

...one Priority Review voucher, to Novartis AG (NYSE:NVS; SIX:NOVN) on approval of malaria drug Coartem artemether/lumefantrine...
BioCentury | Sep 6, 2012
Distillery Therapeutics

Indication: Infectious disease

...Next steps could include evaluating the artemisinin-derived thiocarbonate in models of P. falciparum infection. Coartem artemether/lumefantrine...
Items per page:
1 - 10 of 48